Amgen Inc. $AMGN Shares Bought by Ferguson Wellman Capital Management Inc.

Ferguson Wellman Capital Management Inc. grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 307,566 shares of the medical research company’s stock after purchasing an additional 7,988 shares during the quarter. Amgen makes up about 1.4% of Ferguson Wellman Capital Management Inc.’s holdings, making the stock its 21st largest position. Ferguson Wellman Capital Management Inc. owned 0.06% of Amgen worth $86,795,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC increased its holdings in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the period. Caxton Associates LLP purchased a new position in Amgen during the 1st quarter worth $535,000. Bayforest Capital Ltd acquired a new position in Amgen in the first quarter valued at $41,000. Advisory Alpha LLC raised its holdings in shares of Amgen by 12.2% in the first quarter. Advisory Alpha LLC now owns 919 shares of the medical research company’s stock valued at $286,000 after buying an additional 100 shares during the last quarter. Finally, Integrity Alliance LLC. boosted its stake in shares of Amgen by 66.2% during the first quarter. Integrity Alliance LLC. now owns 8,436 shares of the medical research company’s stock worth $2,628,000 after buying an additional 3,359 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Down 3.4%

Shares of AMGN stock opened at $330.11 on Friday. The business’s fifty day moving average price is $329.19 and its 200 day moving average price is $303.93. The firm has a market capitalization of $177.76 billion, a PE ratio of 25.51, a P/E/G ratio of 3.11 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. Amgen Inc. has a 1-year low of $260.55 and a 1-year high of $346.38.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The company had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.Amgen’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the company earned $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is presently 73.57%.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft boosted their price target on Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a research report on Tuesday, November 11th. UBS Group began coverage on Amgen in a report on Tuesday. They issued a “buy” rating and a $380.00 target price on the stock. Citigroup increased their price target on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a report on Wednesday, September 24th. BMO Capital Markets lifted their price objective on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Finally, The Goldman Sachs Group restated a “buy” rating on shares of Amgen in a research report on Tuesday, November 25th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $338.55.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the sale, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 10,908 shares of company stock worth $3,674,966. 0.76% of the stock is owned by company insiders.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Acquisition of Dark Blue Therapeutics (up to $840M) adds a preclinical AML degrader and strengthens Amgen’s oncology discovery pipeline, a clear long-term revenue/profitability positive if assets advance. Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
• Positive Sentiment: Exclusive Disco Oncology deal valued at about $618M gives Amgen rights to a cancer target, expanding its oncology footprint and signalizing management’s commitment to M&A/licensing as a growth lever. Amgen dances with Disco in $618M cancer target pact
• Positive Sentiment: Completed Phase 1b blinatumomab study in Japan advances Amgen’s leukemia strategy and supports potential label/market expansion in hematologic cancers. Clinical readouts reduce development risk and could drive upside on future data. Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan
• Positive Sentiment: Initiation of a new injection trial for an early-stage obesity candidate signals pipeline diversification beyond oncology and could support medium-term growth as older patents lapse. Amgen Advances Early-Stage Obesity Candidate With New Injection Trial
• Neutral Sentiment: Amgen will present at the 2026 J.P. Morgan Healthcare Conference — an opportunity for management to update guidance and pipeline priorities; results depend on new news or clarity provided. AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
• Neutral Sentiment: Market commentary pieces previewing Q4 2025 results and dividend-stock lists mention Amgen’s efforts to offset a patent cliff with new products; these set expectations but don’t change fundamentals until earnings/data arrive. What to Expect From Amgen’s Q4 2025 Earnings Report
• Negative Sentiment: Coverage noting today’s share decline and market context highlights near-term selling pressure; headlines emphasize the stock fell despite a broader market uptick, which can accelerate outflows. Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
• Negative Sentiment: Truist raised its price target slightly to $319 but kept a “hold” rating; the target implies limited near-term upside relative to current levels, which can pressure momentum investors. Benzinga

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.